PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34392133-9	2021	Both SB203580 and SP600125 suppressed the tramadol effect to enhance the PGD2-stimulated osteoprotegerin release.	pyrazolanthrone	18-26	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	89-104	
25677506-8	2015	Both SB203580 and SP600125, a specific p38 MAP kinase inhibitor and a specific SAPK/JNK inhibitor, respectively, but not PD98059, a specific MEK inhibitor, reduced the PGE1-stimulated OPG release.	pyrazolanthrone	18-26	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	184-187	
24813642-6	2014	PD98059, a specific MEK inhibitor, SB203580, a specific p38 MAP kinase inhibitor, and SP600125, a specific SAPK/JNK inhibitor suppressed the PGD2-stimulated OPG release.	pyrazolanthrone	86-94	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	157-160	
33840687-10	2021	SP600125, an inhibitor of SAPK/JNK, suppressed the levels of PGE2- and PGF2alpha-upregulated osteoprotegerin mRNA expression.	pyrazolanthrone	0-8	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	93-108	
32904295-13	2020	The inhibitors of both p38 MAPK and SAPK/JNK, SB203580 and SP600125, respectively, reduced the tramadol amplification of OPG release stimulated by PGF2alpha.	pyrazolanthrone	59-67	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	121-124	
28163121-8	2017	BIRB0796 and SP600125, a p38 MAP kinase inhibitor and a SAPK/JNK inhibitor, respectively, markedly reduced the amplification by EGCG of the PGE2-stimulated osteoprotegerin release.	pyrazolanthrone	13-21	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	156-171